Offices of Physicians, Mental Health Specialists (U.S.) — NAICS 621112

A Histometrics industry primer for public-market and private investors.

1. Overview

The North American Industry Classification System (NAICS) code 621112 covers the private offices of psychiatrists — physicians holding a Doctor of Medicine (M.D.) or Doctor of Osteopathic Medicine (D.O.) degree who independently practice psychiatry or psychoanalysis. [1] These are the doctors who diagnose mental illness, manage psychiatric medication, and (less often) provide psychotherapy. The line item is narrow on purpose: it is only the doctor's-office slice of a much larger mental-health economy.

Why this matters beyond the doctor's office: mental-health demand is rising structurally while the supply of psychiatrists is capped and aging, which creates durable pricing power and a land-grab for the clinicians themselves. But the classic form of the business — a solo or small-group physician office — is being reshaped by telehealth and by private-equity- and venture-backed platforms that employ psychiatrists at scale.

The central investment question is therefore not simply demand. It is whether an operator can recruit scarce clinicians, fill their schedules, collect reimbursement, maintain clinical quality, and build administrative scale without eroding the clinical trust the business runs on.

• Public-market ways in are few and indirect: a handful of outpatient behavioral-health platforms and virtual-care companies (LifeStance, Talkspace, Teladoc/BetterHelp, Hims & Hers), broader behavioral-hospital operators, plus pharmaceutical exposure to psychiatric drugs. There is no large-cap pure play.
• Private-market ways in are where most of the money and growth sit: owning or building practices, management-services companies, and the growth-equity/venture funds behind the telepsychiatry platforms.

2. What it is and how it is structured

In scope: establishments where M.D./D.O. psychiatrists primarily practice psychiatry or psychoanalysis — solo practices, group practices, and, increasingly, the physician entities inside corporate platforms. Practices may be office-based or located within facilities run by hospitals or health maintenance organizations (HMOs). Services include psychiatric evaluation, medication management, and physician-delivered psychotherapy. [1]

What it explicitly excludes (this matters, because the mental-health market is scattered across several codes):

• 621330 — Offices of Mental Health Practitioners (except Physicians): psychologists, licensed counselors, marriage-and-family therapists, clinical social workers. Most talk therapy lives here, not in 621112.
• 621111 — Offices of Physicians (except Mental Health Specialists): all other doctors.
• 621420 — Outpatient Mental Health and Substance Abuse Centers, and 621498 — mixed-specialty outpatient-care centers.
• 622210 — Psychiatric and Substance Abuse Hospitals and residential facilities: inpatient and residential care. [1]

Ownership mix: historically dominated by physician-owned small businesses. Establishments in this code average about five workers each (65,638 paid workers across 13,449 establishments), confirming a cottage-industry structure. [2] Psychiatry is also one of the medical specialties most likely to be solo practice. [7] Layered on top are two newer ownership forms: (a) employment by hospitals, health systems, and academic medical centers, and (b) corporate platforms that pair a management services organization (MSO) — which supplies scheduling, billing, technology, recruiting, and other nonclinical services — with a physician-owned professional corporation ("friendly PC") to comply with state corporate-practice-of-medicine (CPOM) rules, which in many states bar non-physicians from owning a medical practice. Hims & Hers, for example, discloses that it contracts with affiliated medical groups owned by licensed physicians. [9][26] Our federal source file provides no breakdown of ownership share by solo practice, health system, private equity, or public company.

3. How big it is

Federal business statistics for code 621112 (employer businesses only):

Establishment and firm counts are not interchangeable: one firm can operate several establishments, which is why the ~13,449 establishments (2023) exceed the ~11,973 firms (2022). [2][5]

The undercount is large and important. These figures capture only employer establishments filed under this one NAICS line. They badly understate the true footprint of psychiatric care for three reasons:

1. Most psychiatrists are employed elsewhere. The workforce numbers only ~65,600 total workers (clinicians and support staff) inside 621112 offices, yet the majority of the country's practicing psychiatrists are employed by hospitals, health systems, academic medical centers, the Department of Veterans Affairs (VA), community mental-health centers, and correctional systems — activity classified under hospital, clinic, or government codes, not here.
2. Solo, cash-only psychiatrists with no employees are excluded. County Business Patterns counts only businesses with paid employees, and excludes the self-employed, businesses without an employer identification number (EIN), and most government workers. [3] A psychiatrist practicing alone with no staff is a "nonemployer" tracked in a separate Census program. [4] Our source file does not quantify that missing segment.
3. Concentration is essentially nil. The four largest firms hold just 5.9% of revenue, the top 50 only 22.3%, and the HHI is 16.2 (a standard concentration measure that runs toward 10,000 for a monopoly) — one of the most fragmented industries in the entire economy. [5]

Bottom line: the ~$10.2 billion of "receipts" is a real but small window onto a national spend on psychiatric services that is many times larger once hospital, clinic, government, and cash-pay solo care are counted. Our file provides no industry-wide visit volume, payer mix, revenue per visit, operating margin, clinician turnover, or valuation data.

4. The investable universe

There is no large, pure-play public company whose business is only psychiatrists' offices. The closest public exposures, plus the major private and other owners:

Public companies

Event to watch: UHS agreed to acquire Talkspace for $5.25 per share (~$835 million); shareholders approved the deal, which was subject to closing conditions and expected to close in the third quarter of 2026. [17] That makes Talkspace primarily an event-driven situation rather than a standalone growth story.

Major private / venture-backed platforms (the real growth story)

• Talkiatry — a dedicated in-network psychiatry employer with 800+ full-time psychiatrists; raised $210 million in 2026 (bringing total funding to roughly $452 million), building on earlier rounds led by Andreessen Horowitz with participation from investors such as Perceptive Advisors. [23]
• Geode Health — an outpatient mental-health platform built by KKR combining in-person and virtual care across psychiatrists, psychologists, and therapists. [22]
• Mindpath Health — an in-network, multi-site outpatient platform associated with Centerbridge Partners and Leonard Green & Partners. [25]
• Headway — a venture-backed (Andreessen Horowitz, Accel, Thrive, GV) insurance-enablement network that helps independent clinicians, including prescribers, handle claims, payments, scheduling, and insurance participation rather than owning their practices. [24]
• Other venture-funded prescriber/therapy networks include Grow Therapy, Brightside Health, and Spring Health. Cerebral is a cautionary tale (see Risks): it scaled fast on attention-deficit/hyperactivity-disorder (ADHD) prescribing, then faced federal scrutiny.

Other major owners of psychiatric capacity (not investable as such): hospital systems and academic medical centers (the largest employers of psychiatrists), the VA and other government providers, and tens of thousands of independent physician practices.

5. How the money works

A psychiatry office earns money one visit at a time. The model is labor-intensive and light on medical equipment; the economics turn on a few specific levers:

• Reimbursement per visit and payer mix. Revenue is billed under evaluation-and-management codes (e.g., a follow-up med-management visit), often paired with a psychotherapy add-on, plus a higher-paying initial psychiatric evaluation. The single biggest strategic choice is payer mix: commercial insurance, Medicare, Medicaid, or self-pay (cash). Psychiatry is the specialty least likely to take insurance — private-insurance acceptance had fallen to roughly 55% by 2009–2010, versus about 89% for physicians overall, with a large minority of psychiatrists taking no insurance at all. [12] A cash/out-of-network practice trades volume and access for higher, guaranteed per-visit revenue and near-zero billing hassle. Digital platforms layer additional revenue forms on top of fee-for-service: employer contracts, consumer subscriptions, per-member-per-month (PMPM) fees, and value-based or performance payments.
• Clinician productivity and throughput. Because a medication-management appointment can run 15–30 minutes, a prescriber can see many patients per day; longer therapy sessions are lower-throughput. The operating levers that move the profit-and-loss statement are visits per clinician, schedule-fill rate, panel size, appointment length, new-patient conversion, and time to first appointment. No-shows are a chronic drag unique to behavioral care.
• Clinician cost is the dominant line. The Bureau of Labor Statistics (BLS) reported median annual pay of $269,940 for psychiatrists in May 2025 — which is why recruitment and compensation, not real estate or equipment, are the central cost problem, and why clinician compensation as a percentage of revenue is a headline metric. [13]
• Overhead, collections, and telehealth. Rent, front-office/billing staff, and malpractice insurance are the other main costs; billing denials, days-to-collect, and cash conversion determine how much booked revenue actually lands. Telehealth strips out much of the real-estate cost, which is a core reason virtual psychiatry scales.
• Payer leverage cuts both ways. LifeStance reported that 95% of its patients were insured in 2025, with UnitedHealthcare at 14% and Elevance Health at 15% of revenue. [15] That concentration means a single rate cut, network exclusion, or unfavorable contract renewal can reduce revenue faster than costs fall.
• Platform metrics (for the roll-ups). Companies like LifeStance are judged on clinician headcount, visit volume, revenue per visit, mature-clinic performance versus new-clinic ramp, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization — a cash-earnings proxy). In value-based contracts, clinical outcomes, hospitalization reduction, and patient-reported improvement also feed the economics. LifeStance explicitly measures productivity by clinician visits and ties clinician pay primarily to visits; the binding constraint is how fast it can recruit and retain clinicians. [15]
• The Collaborative Care Model (CoCM). A scalable revenue seam in which one psychiatrist supervises a care manager and a primary-care doctor to treat many patients indirectly, billed under Medicare CoCM codes (99492/99493/99494). It leverages scarce psychiatrist time across a far larger patient panel. [14]

6. What drives demand

• Rising diagnosed prevalence and destigmatization. Roughly 23% of U.S. adults had a mental illness in the past year — about 59 million by the Substance Abuse and Mental Health Services Administration's (SAMHSA) 2023 national survey [10], and about 62 million by the Health Resources and Services Administration's (HRSA) 2024 figure [11] — with nearly half receiving no treatment. Youth mental-health and ADHD diagnoses have surged.
• A structural supply shortage. As of December 2025, about 40% of the U.S. population — roughly 137 million people — lived in a federally designated Mental Health Professional Shortage Area. [11] More than half of U.S. counties have no practicing psychiatrist, the workforce is aging, and projections point to a persistent shortfall of psychiatrists, especially in rural areas and in adult and child psychiatry. [9] Scarcity supports both wages and per-visit pricing.
• Telehealth normalization. Psychiatry is among the most telehealth-suited specialties (mostly conversation and prescribing), which expanded access — especially for rural, mobility-limited, and underserved patients — and enabled national platforms, though it removes neither clinician scarcity, state-licensing requirements, reimbursement risk, nor quality-control obligations.
• Coverage expansion and integration. Mental-health parity rules and Medicare/Medicaid coverage of behavioral services broaden the paying population; employers increasingly buy accessible behavioral care for staff; and behavioral care is being integrated with primary care and hospital systems.
• New treatments. Esketamine (Spravato) for treatment-resistant depression crossed toward $1 billion in annual sales and won a monotherapy approval, and interventional options such as transcranial magnetic stimulation (TMS) create new billable services delivered in psychiatric settings. [21]

7. Regulation

• Corporate practice of medicine (CPOM). State rules restrict non-physician ownership or control of a clinical practice, forcing the MSO/friendly-PC structures used by platforms and direct-to-consumer telehealth companies. Requirements vary materially by state. [9][26]
• Licensure and scope. Psychiatrists are licensed by state medical boards, and a clinician generally must satisfy the rules of the state where the patient is located. Interstate compacts and telehealth registrations ease multi-state practice, but requirements vary by state. [28]
• Controlled substances (a defining feature). Psychiatrists prescribe scheduled drugs (stimulants for ADHD, benzodiazepines), requiring Drug Enforcement Administration (DEA) registration. The Ryan Haight Act normally requires an in-person visit before prescribing controlled substances via telehealth; pandemic-era flexibilities allowing telehealth prescribing without that visit have been extended through December 31, 2026, and the DEA has proposed — but not finalized — a permanent "special registration" pathway. [27] This is the single most important open regulatory question for telepsychiatry.
• Mental-health parity. The Mental Health Parity and Addiction Equity Act (MHPAEA) bars covered plans from imposing more restrictive financial or administrative limits on mental-health benefits than on medical benefits. Federal agencies issued strengthened final rules in 2024 [29], but in 2025 said they would not enforce the new portions pending related litigation and reconsideration; the underlying statute and prior rules remain in force. [30] Enforcement intensity is a swing factor for in-network economics.
• Reimbursement. Medicare's Physician Fee Schedule sets a benchmark rate that commercial payers often follow; Medicare pays for CoCM and has added marriage-and-family therapists and mental-health counselors as billable providers. Fee-schedule cuts are a recurring headwind. [14]
• Privacy and advertising. The Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule protects health information [31], with stricter 42 CFR Part 2 rules for substance-use records. In 2023 the Federal Trade Commission (FTC) finalized an order requiring BetterHelp to pay $7.8 million and barring it from sharing sensitive health data for advertising — a warning shot for behavioral-health data practices. [32]

For investors, regulatory diligence is not a checklist item: it directly shapes clinician supply, allowable ownership structures, reimbursement, marketing, and the scalability of virtual psychiatry.

8. Competitive dynamics and consolidation

The industry is about as fragmented as any in the U.S. economy — CR4 of 5.9% and an HHI of 16.2 [5]. That fragmentation is exactly what has attracted capital:

• Private-equity roll-ups and de novo builds. LifeStance (backed by TPG before its 2021 initial public offering) and platforms like KKR's Geode buy, build, and open multi-clinician practices through add-on acquisitions and new-clinic openings, betting on scale in contracting, billing, and recruiting. [15][22]
• Venture-funded telepsychiatry. Talkiatry, Headway, Grow Therapy, Brightside, and Spring Health raced to build national, insurance-friendly prescriber networks. [23][24]
• Vertical combinations. The proposed UHS–Talkspace deal shows the appeal of pairing facility-based behavioral care with national virtual access. [17]
• Health-system employment. Independent private practice has fallen across medicine (from roughly 60% of physicians in 2012 to about 47% in 2022), and psychiatry follows the trend toward hospital and system employment. [7][8]
• Non-physician substitution. Psychiatric mental-health nurse practitioners (PMHNPs) increasingly handle medication management, and therapists (coded under 621330) absorb talk therapy — letting scarce psychiatrists concentrate on complex cases. This eases the shortage but also commoditizes routine prescribing.

The competitive edge here is not a product; it is access to clinicians and in-network contracts. Competition is local and clinical before it is technological — psychiatrist availability, payer participation, referral relationships, reputation, appointment speed, outcomes, and continuity of care matter more than software, which is rarely a durable moat on its own. Consolidation should continue, but it is constrained by state ownership rules, clinician retention, payer contracts, and the difficulty of standardizing clinical work.

9. Risks

• Telehealth policy reversal. If the DEA lets controlled-substance telehealth flexibilities lapse and reinstates a hard in-person requirement, the telepsychiatry model — especially anything involving stimulants — is disrupted. [27]
• Reimbursement and payer pressure. Medicare fee cuts, narrow networks, prior authorization, payer concentration, and denials squeeze in-network margins; the non-enforcement of the 2024 parity rule adds uncertainty about whether insurers pay adequately for behavioral care. [30]
• Labor is the binding constraint. A structural psychiatrist shortage means wage inflation, burnout, and clinician churn; every growth model is ultimately a recruiting-and-retention model. [9][13]
• Unproven roll-up economics and leverage. LifeStance took years to approach sustained profitability, and BetterHelp's direct-to-consumer therapy revenue has declined with rising customer-acquisition costs. Integration risk and excessive debt are real hazards in private-equity roll-ups. [15][18]
• Affordability and access tension. The specialty's low insurance acceptance limits the addressable population; when deductibles or coverage change, utilization can fall. [12]
• Quality, privacy, and controlled-substance liability. Malpractice, patient-safety and suicide-risk exposure, data breaches, and the misuse of behavioral-health data are all live risks. Cerebral drew federal investigation over telehealth ADHD-stimulant prescribing, and the FTC's BetterHelp order shows the data-privacy downside. [32]
• Statistical risk. Employer datasets may materially understate the number of small or nonemployer practices, so top-down market sizing off this NAICS line alone is unreliable. [3][4]

A platform can grow visits while destroying value if clinician compensation rises faster than reimbursement, patient acquisition becomes expensive, or administrative scale erodes patient and provider trust.

10. How to invest, and the outlook

Public routes (small and imperfect):

• LifeStance (LFST) is the nearest listed pure-play on outpatient mental health, though its clinician base spans psychiatrists, psychologists, and therapists. [15]
• Talkspace (TALK) offers virtual therapy-plus-psychiatry now leaning on insurance coverage, but is primarily an event-driven situation while its UHS acquisition is pending. [16][17]
• Adjacent facility operators: Acadia (ACHC) and Universal Health Services (UHS) give behavioral exposure but sit in the hospital/residential codes, not offices of physicians. [17][20]
• Digital/consumer: Teladoc (TDOC) carries BetterHelp (mostly therapy, shrinking) and Hims & Hers (HIMS) offers direct-to-consumer telehealth. [18][19]
• Pharma: Johnson & Johnson (JNJ) and other central-nervous-system drugmakers monetize psychiatric prescribing (e.g., Spravato). [21]

Private routes (where most of the value is created):

• Direct ownership — buying or building a psychiatry practice or MSO — remains attractive precisely because the industry is so fragmented.
• Growth-equity and venture funds are the vehicle for the telepsychiatry platforms (Talkiatry, Geode, Mindpath, Headway, and peers). [22][23][24][25]
• Ancillary plays: MSO/back-office services, payer-enablement companies, and clinical real estate.
• Key diligence questions: Do clinicians stay? Do mature clinics generate attractive cash returns? Are payer contracts durable? Are claims collected promptly? Is clinical quality measured? Does the ownership structure comply with state CPOM law?

Outlook (forward-looking judgment): the demand backdrop is unusually durable — rising diagnosed need, destigmatization, coverage expansion, and a hard supply ceiling that hands clinicians pricing power. The counterweights are equally real: margins are pressured by a labor shortage and by soft-to-uncertain reimbursement, and the whole telepsychiatry edifice rests on DEA prescribing rules that remain temporary. Expect continued consolidation and platform-building, but treat roll-up profitability as still being proven rather than established — the strongest operators will combine payer access, clinician retention, high schedule utilization, credible outcomes, and disciplined acquisition economics. Technology can improve those economics; it will not substitute for licensed clinicians or clinical trust. Our federal source file contains no industry forecast or complete market-size estimate, so this outlook is an investment judgment, not a federal projection.

---

Sources

1. U.S. Census Bureau, "2022 NAICS Definition — 621112 Offices of Physicians, Mental Health Specialists," 2022. https://www.census.gov/naics/?details=621112&input=621112&year=2022
2. U.S. Census Bureau, "County Business Patterns 2023 (NAICS 621112): establishments, employment, annual and Q1 payroll," 2025. https://www.census.gov/programs-surveys/cbp.html
3. U.S. Census Bureau, "County Business Patterns Methodology (employer-only coverage; excludes self-employed, no-EIN, most government)," 2025. https://www.census.gov/programs-surveys/cbp/technical-documentation/methodology.html
4. U.S. Census Bureau, "Nonemployer Statistics (businesses with no paid employees)," 2025. https://www.census.gov/econ/overview/mu0500.html
5. U.S. Census Bureau, "2022 Economic Census — Concentration/Comparative Statistics (NAICS 621112): firms, receipts, CR4/CR8/CR20/CR50, HHI," 2024. https://www.census.gov/programs-surveys/economic-census.html
6. U.S. Small Business Administration, "Table of Small Business Size Standards (NAICS 621112 = $13.5M receipts)," 2023. https://www.sba.gov/document/support-table-size-standards
7. HealthLeaders / American Medical Association, "Physicians in private practice fell from 60.1% to 46.7% (2012–2022); psychiatry among most common solo specialties," 2024. https://www.healthleadersmedia.com/clinical-care/2012-2022-physicians-working-private-practices-fell-601-467-ama-says
8. American Medical Association, "AMA analysis shows most physicians work outside of private practice," 2023. https://www.ama-assn.org/press-center/ama-press-releases/ama-analysis-shows-most-physicians-work-outside-private-practice
9. Hims & Hers Health, "Form 10-K for the Year Ended December 31, 2025 (affiliated physician-owned medical groups)," 2026. https://www.sec.gov/Archives/edgar/data/1773751/000177375126000022/hims-20251231.htm
10. Substance Abuse and Mental Health Services Administration (SAMHSA), "2023 National Survey on Drug Use and Health — any mental illness prevalence among adults," 2024. https://www.samhsa.gov/data/
11. Health Resources and Services Administration (HRSA), "State of the Behavioral Health Workforce, 2025 (≈62M adults with mental illness in 2024; 40% of population / 137M in a Mental Health Professional Shortage Area as of Dec. 2, 2025)," 2025. https://bhw.hrsa.gov/sites/default/files/bureau-health-workforce/data-research/Behavioral-Health-Workforce-Brief-2025.pdf
12. Bishop TF, et al., "Acceptance of Insurance by Psychiatrists and the Implications for Access to Mental Health Care," JAMA Psychiatry, 2014. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/1785174
13. U.S. Bureau of Labor Statistics, "Occupational Employment and Wages — May 2025 (psychiatrists, median $269,940)," 2026. https://www.bls.gov/news.release/ocwage.t01.htm
14. American Psychiatric Association, "Getting Paid in the Collaborative Care Model — Medicare CoCM CPT codes 99492/99493/99494," 2024. https://www.psychiatry.org/psychiatrists/practice/professional-interests/integrated-care/get-paid
15. LifeStance Health Group, "Form 10-K for the Year Ended December 31, 2025 (8,040 clinicians across 33 states; ~9.0M visits; payer mix)," 2026. https://www.sec.gov/Archives/edgar/data/1845257/000119312526071462/lfst-20251231.htm
16. Talkspace, "Form 10-K for the Year Ended December 31, 2025 (~$228.9M revenue; ~1,617,000 payer sessions)," 2026. https://www.sec.gov/Archives/edgar/data/1803901/000119312526105146/talk-20251231.htm
17. Talkspace, "Stockholders Vote to Approve Acquisition by UHS ($5.25/share, ~$835M; expected Q3 2026 close)," 2026. https://talkspace.gcs-web.com/news-releases/news-release-details/talkspace-stockholders-vote-approve-acquisition-uhs
18. Teladoc Health, "Form 10-K for the Year Ended December 31, 2025 (BetterHelp segment)," 2026. https://www.sec.gov/Archives/edgar/data/1477449/000147744926000012/tdoc-20251231.htm
19. Hims & Hers Health, "Form 10-K for the Year Ended December 31, 2025 (direct-to-consumer telehealth)," 2026. https://www.sec.gov/Archives/edgar/data/1773751/000177375126000022/hims-20251231.htm
20. Acadia Healthcare, "Form 10-K for the Year Ended December 31, 2025," 2026. https://www.sec.gov/Archives/edgar/data/1520697/000119312526078266/achc-20251231.htm
21. PharmaVoice / FiercePharma, "J&J's Spravato (esketamine) heads for blockbuster status; monotherapy approval," 2024–2025. https://www.pharmavoice.com/news/jnj-spravato-blockbuster-depression/730988/
22. KKR, "KKR Forms Geode Health to Increase Access to Mental Health Care," 2021. https://geode.health/news/kkr-forms-geode-health-to-increase-access-to-mental-health-care
23. Behavioral Health Business, "Talkiatry Raises $210M (total funding ~$452M; 800+ psychiatrists; Andreessen Horowitz-led backing, Perceptive Advisors among earlier participants)," 2026. https://bhbusiness.com/2026/02/12/talkiatry-raises-210m-to-expand-digital-ai-powered-psychiatry-practice/
24. Andreessen Horowitz, "Investing in Headway (insurance-enablement network for independent clinicians)," 2021. https://a16z.com/announcement/investing-in-headway/
25. Centerbridge Partners / Leonard Green & Partners, "Mindpath Health portfolio listings (in-network, multi-site outpatient mental-health platform)," 2026. https://www.centerbridge.com/private-equity
26. American Medical Association, "State Advocacy Update: Legislative Approaches to Curb Corporate Influence in Health Care (corporate practice of medicine)," 2025. https://www.ama-assn.org/health-care-advocacy/advocacy-update/oct-3-2025-state-advocacy-update
27. Drug Enforcement Administration / McDermott+, "DEA Extends Telemedicine Flexibilities for Controlled-Substance Prescribing Through December 31, 2026; proposed special registration," 2025. https://www.dea.gov/documents/2025/dea-extends-telemedicine-flexibilities
28. Telehealth.HHS.gov, "Licensing Across State Lines," 2025. https://telehealth.hhs.gov/licensure/licensing-across-state-lines
29. Centers for Medicare & Medicaid Services, "Departments Issue Final Rules Strengthening Access to Mental Health and Substance Use Disorder Benefits (MHPAEA 2024)," 2024. https://www.cms.gov/newsroom/press-releases/departments-labor-health-and-human-services-treasury-issue-final-rules-strengthening-access-mental
30. U.S. Departments of Labor, Health and Human Services, and Treasury, "Statement Regarding Enforcement of the Final Rule on Requirements Related to MHPAEA (2025 non-enforcement)," 2025. https://www.cms.gov/files/document/statement-regarding-enforcement-final-rule-requirements-related-mhpaea.pdf
31. U.S. Department of Health and Human Services, "The HIPAA Privacy Rule," n.d. https://www.hhs.gov/hipaa/for-professionals/privacy/index.html
32. Federal Trade Commission, "FTC Gives Final Approval to Order Banning BetterHelp from Sharing Sensitive Health Data for Advertising ($7.8M)," 2023. https://www.ftc.gov/news-events/news/press-releases/2023/07/ftc-gives-final-approval-order-banning-betterhelp-sharing-sensitive-health-data-advertising